1326714-87-7 Usage
Description
1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carbonitrile is a complex chemical compound characterized by its unique molecular structure. It features a tetrahydro-2H-pyran-2-yl group, a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, and a 1H-indazole-3-carbonitrile group. 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carbonitrile holds potential in pharmaceutical research and drug development due to its distinctive structural attributes and possible biological activities.
Uses
Used in Pharmaceutical Research and Drug Development:
1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carbonitrile is used as a building block in the synthesis of new chemical compounds with specific properties. Its unique structure suggests potential use as a drug candidate, contributing to the development of novel therapeutic agents.
Used in Analytical Chemistry:
In the field of analytical chemistry, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carbonitrile may serve as a reference standard. Its distinct characteristics can be utilized for calibration and quality control purposes, ensuring accurate and reliable analytical results.
Check Digit Verification of cas no
The CAS Registry Mumber 1326714-87-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,2,6,7,1 and 4 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1326714-87:
(9*1)+(8*3)+(7*2)+(6*6)+(5*7)+(4*1)+(3*4)+(2*8)+(1*7)=157
157 % 10 = 7
So 1326714-87-7 is a valid CAS Registry Number.
1326714-87-7Relevant articles and documents
7-AMINOFUROPYRIDINE DERIVATIVES
-
, (2011/09/15)
Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
